

MEDICIS PHARMACEUTICAL CORP  
Form 8-K  
March 20, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
March 18, 2009**

Date of Report (Date of earliest event reported)  
**Medicis Pharmaceutical Corporation**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State of Incorporation)

**001-14471**  
(Commission File Number)

**52-1574808**  
(IRS Employer  
Identification Number)

**7720 North Dobson Road**  
**Scottsdale, Arizona 85256**  
(Address of principal executive offices) (Zip Code)  
**(602) 808-8800**  
(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 18, 2009, Medicis Pharmaceutical Corporation (the Company ) entered into a Settlement Agreement (the Settlement Agreement ) with Teva Pharmaceutical Industries Ltd. ( Teva ). In connection with the Settlement Agreement, the Company and Teva agreed to terminate all legal disputes between them relating to SOLODYN® (minocycline HCl, USP) Extended Release Tablets. In addition, Teva confirmed that the Company's patents relating to SOLODYN® are valid and enforceable, and cover Teva's activities relating to its generic product under Abbreviated New Drug Application (ANDA) #65-485. Further, subject to the terms and conditions contained in the Settlement Agreement:

- § Teva agreed to immediately stop all further shipments of generic SOLODYN®;
- § the Company agreed to release Teva from liability arising from any prior sales of its generic SOLODYN® which were not authorized by the Company; and
- § Teva has the option to market its generic versions of SOLODYN® 45mg, 90mg and 135mg under the SOLODYN® intellectual property rights belonging to the Company commencing in November 2011, or earlier under certain conditions.

A press release dated March 18, 2009 announcing the execution of the Settlement Agreement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 9.01 Exhibits.**

(d) Exhibits

99.1 Press Release dated March 18, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 19, 2009

By: /s/ Jason D. Hanson  
Jason D. Hanson  
Executive Vice President, General  
Counsel and Corporate Secretary